Compare AIDX & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIDX | NOTV |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.8M |
| IPO Year | N/A | 1997 |
| Metric | AIDX | NOTV |
|---|---|---|
| Price | $1.01 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 51.8K | ★ 614.5K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $1.19 | $0.22 |
| 52 Week High | $14.09 | $3.31 |
| Indicator | AIDX | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 17.69 | 45.28 |
| Support Level | N/A | $0.24 |
| Resistance Level | $1.66 | $0.34 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 13.14 | 30.72 |
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.